AbCellera Biologics (ABCL) Non-Current Deffered Revenue (2020 - 2026)
AbCellera Biologics' (ABCL) quarterly Non-Current Deffered Revenue came in at $5.8 million in Q3 2025, down 27.78% YoY from $8.1 million in Q3 2024, and down 49.71% on a QoQ basis from $11.6 million in Q2 2025.
AbCellera Biologics (ABCL) Non-Current Deffered Revenue (2020 - 2026) Analysis & Trends
AbCellera Biologics (ABCL) has 6 years of Non-Current Deffered Revenue data on file, last reported at $5.8 million in Q3 2025.
- Quarterly Non-Current Deffered Revenue fell 27.78% year-over-year to $5.8 million in Q3 2025, while the trailing twelve-month figure through Sep 2025 was $5.8 million (down 27.78% YoY) and the FY2024 annual result came in at $5.7 million, down 30.45% from the prior year.
- Non-Current Deffered Revenue fell to $5.8 million in Q3 2025, from $11.6 million in the prior quarter.
- In the past five years, Non-Current Deffered Revenue ranged from a high of $64.8 million in Q2 2022 to a low of $5.7 million in Q4 2024.
- A 5-year average of $27.0 million and a median of $19.5 million in 2022 frame the typical range for Non-Current Deffered Revenue.
- Annual changes were most pronounced in 2022 — Non-Current Deffered Revenue surged 123.29% — and 2023, when it plunged 73.66%.
- Tracing ABCL's Non-Current Deffered Revenue over 5 years: stood at $27.4 million in 2021, then fell by 28.8% to $19.5 million in 2022, then plunged by 58.01% to $8.2 million in 2023, then sank by 30.45% to $5.7 million in 2024, then gained by 2.63% to $5.8 million in 2025.
- The last three Non-Current Deffered Revenue figures came in at $5.8 million (Q3 2025), $11.6 million (Q2 2025), and $13.8 million (Q1 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 220.40 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | AbCellera Biologics | 3.49 Bn | 3.49 Bn | - | 40.45 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 40.45 Mn |
| Dec 31, 2025 | 3.50 Mn |
| Sep 30, 2025 | 5.85 Mn |
| Jun 30, 2025 | 11.63 Mn |
| Mar 31, 2025 | 13.75 Mn |
| Dec 31, 2024 | 5.70 Mn |
| Sep 30, 2024 | 8.10 Mn |
| Jun 30, 2024 | 7.97 Mn |
| Mar 31, 2024 | 8.57 Mn |
| Dec 31, 2023 | 8.20 Mn |
| Sep 30, 2023 | 16.38 Mn |
| Jun 30, 2023 | 27.72 Mn |
| Mar 31, 2023 | 25.42 Mn |
| Dec 31, 2022 | 19.52 Mn |
| Sep 30, 2022 | 62.20 Mn |
| Jun 30, 2022 | 64.80 Mn |
| Mar 31, 2022 | 64.15 Mn |
| Dec 31, 2021 | 27.41 Mn |
| Sep 30, 2021 | 59.68 Mn |
| Jun 30, 2021 | 46.62 Mn |